淋巴缺血是直肠腺癌患者接受长期化疗或放射治疗的不良预后因素
Ioannis M Koukourakis1, Ioannis Georgakopoulos1, Dimitra Desse1
1Radiation Oncology Unit, 1st Department of Radiology, Medical School, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Radiation oncology journal
|January 3, 2025
概括
对直肠腺癌的化学放射治疗 (CRT) 显著降低了淋巴细胞数量,导致淋巴衰竭. 这种淋巴缺血与较差的瘤回归和较高的远程转移风险有关,这凸显了在治疗期间需要保护免疫系统的需要.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 辐射疗法 辐射疗法
背景情况:
- 新辅助化学放射治疗 (CRT) 是局部晚期直肠腺癌的标准.
- 新出现的数据表明免疫疗法在不匹配修复缺陷直肠癌中的有效性,突出显示了免疫系统的作用.
- 放射治疗 (RT) 可以刺激抗瘤免疫力,但也会导致淋巴缺血,可能阻碍免疫反应.
研究的目的:
- 在直肠腺癌患者中研究CRT对外围血液淋巴细胞计数 (LC) 的影响.
- 确定CRT诱导的淋巴缺血对瘤反应和患者预后的影响.
主要方法:
- 对33名用CRT治疗的直肠腺癌患者的回顾性分析.
- 在CRT前后监测周围血液淋巴细胞计数.
- 在LC,瘤回归和生存结果之间的相关性分析.
主要成果:
- 在CRT后观察到LC的显著下降 (2,184/μL到517/μL,p<0.001).
- 较差的瘤回归与较低的CRT后LC相关 (p = 0.036).
- 淋巴缺血与远程无转移生存率较差相关 (p = 0.003),低LC患者中有44.5%患有远程转移,高LC患者为0%.
结论:
- 淋巴缺血是接受新辅助CRT的直肠腺癌患者的显著不良事件.
- 由CRT诱导的淋巴衰竭对瘤反应和预后有影响.
- 在CRT期间保护免疫系统是未来临床研究的关键领域.
更多相关视频
07:45Author Spotlight: A Model to Study the Systemic and Local Dynamics of CD8+ T Cells During LN Metastasis
Published on: January 26, 2024
1.6K
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
177
相关概念视频
Stem Cell Therapy for Tissue Regeneration
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Bone Marrow Sampling and Transplants
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Kidney Transplant II: Surgical Procedure
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
